ARROWSTREET CAPITAL, LIMITED PARTNERSHIP
Position in FATE — Fate Therapeutics Inc
CIK 1164508
BOSTON, MA
Position in FATE
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$81,475
+$39,268 QoQ
Shares Held
30,176
+18.0% QoQ
Ownership
0.025%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#79
of 156 holders
Holding Since
Sep 2020
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in FATE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026ARROWSTREET CAPITAL, LIMITED PARTNERSHIP holds $2,515,799,583 across 71 Biotechnology names. FATE ranks #68 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
738,378 | $366,774,503 | |
| 2 | INCY |
Incyte Corp
|
2,744,958 | $311,168,438 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
393,685 | $245,478,344 | |
| 4 | EXEL |
Exelixis, Inc.
|
4,365,926 | $237,550,033 | |
| 5 | GMAB |
Genmab A/S
|
4,975,324 | $136,672,150 | |
| 6 | RPRX |
Royalty Pharma plc
|
2,435,341 | $136,549,569 | |
| 7 | HALO |
Halozyme Therapeutics, Inc.
|
1,704,623 | $133,420,842 | |
| 8 | ONC |
BeOne Medicines Ltd.
|
249,758 | $71,173,537 |
All Filings in FATE
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $81,475 | 30,176 | Shares | Defined | 2026-08-13 | |
| 2024-12-31 | $42,207 | 25,580 | Shares | Defined | 2025-02-12 | |
| 2024-09-30 | $112,343 | 32,098 | Shares | Defined | 2024-11-14 | |
| 2021-09-30 | $1,487,677 | 25,100 | Shares | Defined | 2021-11-12 | |
| 2021-06-30 | $329,802 | 3,800 | Shares | Defined | 2021-08-13 | |
| 2020-12-31 | $6,332,001 | 69,636 | Shares | Defined | 2021-02-12 | |
| 2020-09-30 | $1,365,335 | 34,159 | Shares | Defined | 2020-11-12 | |
| No filing history on record for this holder in this stock. | ||||||